Firma Clinical Research: prioritize patients in your trials

By Jenni Spinner

- Last updated on GMT

(kevajefimija/iStock via Getty Images Plus)
(kevajefimija/iStock via Getty Images Plus)

Related tags Patient centricity patient engagement Patient recruitment Firma Clinical Research Clinical trials Contract research organization

A leader from the CRO discusses the vital role participants play in a clinical study’s success, and what it truly means to be patient centric.

Melissa Nezos (MN), vice president of clinical operations with contract research organization (CRO) Firma Clinical Research, spoke with Outsurcing-Pharma (OSP) about what it means to be truly patient centric, and why it’s vital to make the trial participant the star of the show.

OSP: What does it mean for clinical research to be “patient focused”?

MN: A patient-focused study puts the patient experience in the forefront of everything that happens in the trial and reduces the patient burden; that includes receiving feedback from the actual patients on the protocol, mapping out the patient flow on the study, and understanding the patient and caregiver experience. A patient-centric trial may include home health services, telemedicine and the involvement of a patient advisory board and patient advocacy groups.

OSP: How do you think clinical trial professionals’ attitudes toward and treatment of patient participants has evolved in recent years?

MN: The industry is typically slow to evolve, but the COVID-19 pandemic has pushed changes along. Clinical trial professionals are now more aware of how patient centricity can provide a competitive advantage, which includes increased protocol compliance, decreased protocol deviations and better and cleaner data collection.

As the industry is figuring out how to operationalize decentralized trials, study professionals are working with organizations like Firma to bring home trial services to their studies and put greater focus on patient needs.

OSP: Similarly, could you share your perspective on how clinical trials themselves have evolved in recent years?

MN: A big change has been the use of a variety of technology solutions, such as telemedicine, electronic site binders and wearables. This tech enables us to obtain data faster and in a more precise manner.

Plus, the industry is using data analytics to evaluate risks and make decisions about studies. Overall, more dedicated research resources will be in the home setting, which mirrors what we are seeing in healthcare in general.

OSP: Do you feel in general that most clinical trials are truly patient centric—if not, where do they fall short?

Melissa Nezos, VP of clinical operations, Firma Clinical Research

MN: There definitely is a shift going on to have the patient as the center of the trial. The industry, and more importantly patients, have come to expect integration and continued enhancement of the patient perspective within drug development. The challenge to the industry now is to better respond to meet these increasing expectations and better serve the needs of the patients. 

OSP: What does viewing “patients as partners” mean to you?

MN: Patients as partners means engaging with patients from the beginning of the study. We can do this by asking patients how procedures and protocols impact them. We can talk to patients about their comorbidities, personal needs and challenges, daily life, family and caregiver situation and economic status.

OSP: Why is it important to put patients closer to the center of clinical research?

MN: If we put patients first, we encourage more participation overall in clinical research. That’s important because billions of dollars have been spent trying to recruit patients to studies. Plus, by enhancing and “normalizing” the trial experience, we can increase participation in under-represented groups, resulting in more robust results that help bring medicines to all people who need them.

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more